The American College of Chest Physicians’ (CHEST) series of guidelines for the management and treatment of pulmonary arterial hypertension (PAH) in adults, which was published this summer in the CHEST journal, has been officially endorsed by the country’s leading pulmonary hypertension association, the Pulmonary Hypertension Association…
News
Sorrento Therapeutics, Inc., a late-stage clinical oncology company, has announced that it will advance with its immunotherapy targeting WNT1-Inducible Signaling Protein-1 (WISP1) for the potential treatment of idiopathic pulmonary fibrosis (IPF). IPF is a chronic and fatal disease that occurs in individuals between 50 and 70 years of…
UCLA researchers have shown that oxidized lipids may contribute to pulmonary hypertension (PH), a progressive and incurable disease that is responsible for narrowing the small blood vessels in the lungs. In a study entitled “Apolipoprotein A-I Mimetic Peptide 4F Rescues Pulmonary Hypertension by Inducing MicroRNA-193-3p”…
The Pulmonary Hypertension Association (PHA) is hosting a webinar about the health value of exercise for pulmonary hypertension patients. The event, called “Exercising Mindfully with PH,” will take place Thursday, August 28 at the PHA head office, and will be presented by Rana Lee Adawi…
A group of researchers from the University of Pécs, Hungary, have attempted to understand the mechanism by which pulmonary vascular remodeling initiates right ventricular failure and hypoxia, one of the leading causes behind the mortality rates associated with Pulmonary Hypertension (PH). Sildenafil, known more commonly by its…
Although clinically unexplored, pulmonary hypertension (PH) in the setting of idiopathic pulmonary fibrosis (IPF) is a significant reality in many patients (32 to 85%). IPF is an irreversible disease in which progressive loss of lung function due to fibrosis occurs, diminishing the lung’s capacity to absorb oxygen…
The Pulmonary Hypertension Association (PHA) is organizing another edition of the annual educational forum “PHA On the Road,” intended to provide support to not only patients and families living with pulmonary hypertension (PH), but also medical professionals. Houston, Texas and San Diego, California are the two locations…
Systemic sclerosis (SSc) is a disease that affects multiple organs, with the heart being frequently affected and correlating with a poor outcome for the patient. Different heart structures can be affected leading to pericardial disease, arrhythmias, conduction system abnormalities, direct myocardial disease such as pulmonary arterial hypertension, myositis, cardiac failure,…
Dr. Francisco Boin of the Scleroderma Center at The Johns Hopkins University School of Medicine is organizing a live and free webinar about scleroderma, a rare autoimmune disease, taking place tomorrow, August 21, at 1:00 p.m. EDT. The center is one of the largest scleroderma specialty clinics in the world and is…
GeNo LLC, a pharmaceutical company developing a line of innovative nitric oxide drug products, is currently testing next-generation inhaled nitric oxide (NO) drug delivery systems for use in both hospital and outpatient settings that could come to impact treatments for those with pulmonary hypertension. Nitric oxide is a naturally…
A team of researchers from the University Medical Center Groningen in Holland, has identified three baseline variables that can become treatment goals in children suffering with pulmonary arterial hypertension (PAH). PAH is rare in infants, however, it is a severe condition that rapidly deteriorates if left untreated.
Funding and awards from disease advocacy groups are usually given to scientists or clinicians and earmarked for research on new therapies and treatment options. While the Pulmonary Hypertension Association (PHA) is certainly well-known for funding research into PH, the organization is also passionate about empowering…
